keyword
respiratori
viru
solid
organ
transplant
hematopoiet
stem
cell
transplant
respiratori
viral
infect
common
caus
infect
solid
organ
hematopoiet
stem
cell
recipi
respiratori
viral
infect
caus
signific
morbid
mortal
immunocompromis
patient
treatment
option
respiratori
virus
limit
prevent
vital
follow
transplant
common
respiratori
viral
infect
rvi
import
caus
morbid
mortal
follow
solid
organ
transplant
sot
hematopoiet
stem
cell
transplant
hsct
rvi
typic
caus
respiratori
syncyti
viru
rsv
influenza
parainfluenza
rhinoviru
adenoviru
human
metapneumoviru
hmpv
also
increas
recognit
human
coronaviru
human
bocaviru
popul
addit
sot
hsct
patient
respiratori
infect
caus
virus
less
commonli
associ
respiratori
tract
cytomegaloviru
cmv
human
herpesvirus
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
articl
focus
epidemiolog
outcom
specif
prevent
treatment
option
rvi
sot
hsct
patient
rvi
wellrecogn
caus
morbid
mortal
follow
sot
especi
within
thorac
transplant
popul
recent
prospect
surveil
lung
transplant
recipi
spain
found
overal
rate
respiratori
virus
asymptomat
symptomat
per
patientyear
significantli
higher
rate
rvi
per
patientyear
symptomat
patient
nasopharyng
swab
collect
asymptomat
patient
posit
time
compar
posit
symptomat
patient
frequent
detect
rvi
symptomat
patient
picornavirus
rhinoviru
enteroviru
follow
coronaviru
influenza
symptomat
rvi
detect
progress
lower
respiratori
tract
infect
lrti
patient
prospect
swiss
studi
report
similar
result
rvi
incid
per
patientyear
detect
respiratori
virus
screen
symptomat
patient
rhinovirusenteroviru
common
rvi
human
bocaviru
identifi
report
caus
upper
respiratori
infect
uri
fever
wheez
lrti
diarrhea
normal
host
play
unclear
role
sot
recipi
parainfluenza
rsv
hmpv
influenza
frequent
found
virus
lrti
associ
higher
rate
hospit
analys
rvi
lung
transplant
recipi
report
rate
infect
detect
time
frequent
symptom
present
tabl
report
risk
rvi
lung
transplant
patient
includ
increas
calcineurin
inhibitor
level
age
less
year
underli
caus
transplant
cystic
fibrosi
note
sot
patient
rvi
hsct
recipi
wellcharacter
caus
signific
morbid
mortal
report
incid
rvi
hsct
recipi
vari
earlier
report
use
antigen
detect
cultur
use
polymeras
chain
reaction
pcr
test
see
tabl
bocaviru
mention
earlier
also
play
unclear
role
hsct
popul
report
dissemin
bocaviru
pediatr
hsct
recipi
risk
factor
progress
lrti
includ
age
greater
year
lymphopenia
neutropenia
alternativenongenoident
sibl
donor
chronic
graftversushost
diseas
gvhd
sever
public
attempt
delin
morbid
mortal
follow
rvi
thorac
transplant
recipi
specif
respect
acut
reject
chronic
lung
allograft
dysfunct
clad
bronchiol
obliteran
syndrom
bo
studi
spain
mention
earlier
lrti
associ
signific
chang
lung
function
forc
expiratori
volum
second
fev
month
follow
infect
nest
casecontrol
analysi
report
signific
associ
rvi
within
month
acut
reject
hazard
ratio
hr
confid
interv
ci
p
altern
swiss
studi
similar
incid
rate
found
associ
clad
compromis
longterm
surviv
follow
lung
transplant
although
associ
previou
viral
infect
explor
publish
literatur
definit
link
remain
unclear
pool
incid
rate
clad
metaanalysi
mention
earlier
virusposit
case
case
compar
virusneg
case
limit
number
overal
event
link
could
confirm
howev
publish
epidemiolog
link
rvi
clad
well
data
biolog
plausibl
mechan
underli
causal
relationship
addit
recent
larg
retrospect
cohort
n
lung
transplant
recipi
found
independ
associ
rvi
develop
clad
within
next
month
hr
ci
p
paulsen
danzigerisakov
publish
attribut
mortal
caus
lrti
hsct
respiratori
viru
vari
report
commonli
involv
influenza
rsv
adenoviru
hmpv
import
risk
factor
mortal
hsct
popul
includ
lymphopenia
corticosteroid
mgkg
viral
bacteri
coinfect
bo
follow
allogen
stem
cell
transplant
also
associ
signific
morbid
mortal
recogn
risk
factor
bo
follow
hsct
gvhd
evid
rvi
may
play
role
well
array
diagnost
tool
rvi
immunocompromis
patient
greatli
increas
last
year
provid
increas
sensit
well
decreas
process
time
gener
test
rvi
move
away
viral
antigen
cultur
method
reli
heavili
molecular
method
realtim
quantit
qualit
revers
transcript
pcr
test
wellestablish
method
identifi
viral
infect
incorpor
mani
guidelin
use
multiplex
platform
test
multipl
virus
simultan
singl
sampl
common
sensit
molecular
diagnost
tool
improv
issu
asymptomat
viral
shed
sampl
method
becom
relev
ever
note
earlier
asymptomat
viral
shed
seen
frequent
includ
report
asymptomat
rsv
shed
hsct
recipi
day
persist
rhinoviru
detect
month
lung
transplant
recipi
abil
current
molecular
test
method
detect
viru
sampl
viral
copi
combin
prolong
viral
shed
sot
hsct
recipi
creat
challeng
clinician
tri
determin
whether
posit
molecular
test
indic
true
pathogen
sourc
sampl
method
use
import
consider
respiratori
sampl
routin
obtain
aspirateswash
swab
nasopharynx
np
oropharynx
op
well
invas
collect
method
bronchoalveolar
lavag
bal
howev
choic
upper
respiratori
sampl
collect
methodolog
optim
viral
recoveri
uncertain
children
hospit
respiratori
infect
sensit
rvi
detect
np
aspir
report
versu
nasal
swab
sensit
similar
comparison
np
swab
without
op
swab
immunocompet
children
found
higher
sensit
np
swab
rvi
greater
equal
op
swab
combin
test
increas
detect
depend
viru
investig
adult
report
higher
sensit
np
wash
np
swab
op
swab
note
maxim
sensit
achiev
combin
method
rvi
prevent
key
compon
minim
infect
subsequ
complic
intervent
patient
specif
antivir
prophylaxi
follow
transplant
immun
follow
transplant
common
rvi
immun
avail
influenza
discuss
later
vaccin
mani
rvi
still
develop
commerci
avail
addit
intervent
level
health
care
system
decreas
incid
rvi
includ
appropri
use
respiratori
contact
precaut
screen
visitor
immun
health
care
staff
intervent
includ
gener
us
center
diseas
control
prevent
cdc
recommend
reduc
health
careassoci
pneumonia
prevent
rvi
hsct
recipi
also
address
joint
cdc
infecti
diseas
societi
american
idsa
american
societi
blood
marrow
transplant
guidelin
well
http
asheducationbookhematologylibrari
intervent
univers
mask
use
health
care
staff
visitor
hsct
unit
strict
isol
patient
mandatori
hand
wash
visitor
restrict
children
less
year
age
shown
significantli
reduc
incid
rvi
use
center
virusspecif
outcom
prevent
treatment
respiratori
syncyti
viru
epidemiolog
risk
attribut
mortal
rsv
long
recogn
concern
pathogen
immunocompromis
host
increas
mortal
infect
involv
lower
respiratori
tract
solid
organ
popul
lung
transplant
recipi
increas
risk
rsvrelat
mortal
morbid
compar
organ
incid
rsv
lung
transplant
recipi
variabl
account
roughli
rvi
infect
risk
factor
morbid
mortal
clearli
defin
report
young
age
year
recent
transplant
preexist
lung
disord
recent
reject
multiviscer
transplant
risk
factor
rsv
infect
follow
hsct
depend
sever
factor
includ
patient
age
type
transplant
incid
rsv
infect
follow
hsct
report
allogen
autolog
pediatr
patient
greatest
risk
rsv
sever
risk
factor
report
rsv
well
progress
lrti
sever
infect
hsct
risk
factor
rsv
includ
less
month
posttranspl
preengraft
younger
year
older
year
age
gvhd
relaps
diseas
smoke
risk
present
lrti
progress
lrti
includ
lack
rsvdirect
therapi
highdos
total
bodi
irradi
respiratori
coinfect
absolut
neutrophil
count
less
cellsmm
absolut
lymphocyt
count
alc
less
cellsmm
contrast
alc
greater
cellsmm
protect
progress
lrti
attribut
mortal
rsv
infect
report
sever
public
mortal
approach
untreat
hsct
patient
decreas
prompt
support
care
andor
treatment
recent
assess
adult
hospit
patient
report
mortal
hsct
sot
recipi
set
ribavirin
treatment
age
greater
year
lymphopenia
risk
factor
mortal
compar
nontranspl
patient
recent
report
pediatr
hsct
recipi
also
show
better
outcom
histor
report
progress
lrti
mortal
primari
treatment
modal
intraven
immunoglobulin
ivig
supplement
although
transplant
patient
like
increas
risk
morbid
mortal
especi
lrti
pediatr
patient
present
clinic
upper
respiratori
tract
infect
urti
symptom
also
manag
good
outcom
outpati
set
therefor
although
rsv
infect
sot
hsct
popul
associ
increas
morbid
mortal
precis
determin
impact
remain
elus
overal
outcom
seem
improv
time
addit
gener
prevent
measur
review
earlier
us
food
drug
administr
fda
approv
agent
prevent
sever
rsv
infect
palivizumab
palivizumab
human
monoclon
antibodi
target
f
glycoprotein
rsv
approv
prevent
rsv
highrisk
patient
less
year
age
recommend
publish
american
academi
pediatr
palivizumab
prophylaxi
infant
children
less
month
age
specif
predispos
condit
respect
immunocompromis
children
specif
recommend
made
asid
consid
prophylaxi
profoundli
immunocompromis
patient
younger
month
age
recent
multidisciplinari
consensu
confer
itali
referenc
lack
adequ
clinic
trial
statist
power
recommend
palivizumab
children
primari
acquir
immunodefici
practic
use
palivizumab
rsv
prophylaxi
immunocompromis
patient
vari
wide
approxim
survey
pediatr
sot
center
use
palivizumab
prophylaxi
candid
recipi
target
infant
month
old
extend
use
month
provid
palivizumab
patient
year
old
gave
palivizumab
patient
year
age
variabl
practic
like
caus
limit
data
efficaci
palivizumab
prophylaxi
immunocompromis
patient
retrospect
pediatr
hsct
cohort
memori
sloan
ketter
cancer
center
n
nearli
half
highrisk
patient
receiv
intraven
iv
palivizumab
palivizumab
treatment
group
develop
rsv
compar
receiv
prophylaxi
similarli
approach
limit
palivizumab
hsct
pediatr
patient
younger
month
either
chronic
oxygen
requir
sever
combin
immunodefici
pretranspl
day
posttranspl
found
increas
incid
rsv
patient
outcom
compar
histor
control
wider
use
palivizumab
time
allow
delay
hsct
also
report
effect
strategi
prevent
seriou
rsv
infect
hsct
candid
rsv
urti
condit
one
report
strategi
delay
transplant
symptom
resolut
neg
repeat
rsv
test
result
signific
reduct
rsv
pneumonia
follow
transplant
improv
mortal
compar
patient
whose
transplant
delay
care
thought
must
given
underli
diseas
process
risk
progress
well
type
transplant
make
decis
delay
hsct
sever
manag
option
rsv
consid
report
literatur
although
report
improv
outcom
placebocontrol
trial
clearli
delin
indic
efficaci
treatment
random
control
trial
accru
hsct
patient
year
report
aerosol
ribavirin
decreas
rsv
viral
load
compar
support
care
significantli
improv
outcom
ribavirin
broadspectrum
nucleosid
analogu
activ
dna
rna
virus
report
toxic
inhal
ribavirin
includ
bronchospasm
cough
nausea
rash
decreas
pulmonari
function
iv
ribavirin
advers
effect
includ
hemolysi
hyperbilirubinemia
leukopenia
wherea
oral
ribavirin
caus
anemia
rash
present
aerosol
ribavirin
remain
fdaapprov
drug
treatment
sever
rsv
infect
approv
use
children
immunomodul
also
investig
includ
ivig
antirsv
monoclon
antibodi
palivizumab
lack
clear
evid
efficaci
wide
variat
manag
rsv
exist
recommend
guidelin
publish
hsct
sot
patient
although
base
best
avail
data
strong
recommend
mani
case
exampl
sot
recommend
rsv
lrti
consider
aerosol
ribavirin
combin
rsv
ivig
palivizumab
increas
mortal
hsct
patient
recommend
treatment
within
popul
stronger
base
publish
report
well
selfreport
treatment
strategi
survey
sot
center
lung
heartlung
recipi
often
treat
urti
lrti
rsv
lrti
may
treat
nonlung
transplant
sot
recipi
although
inconsist
retrospect
prospect
studi
report
improv
outcom
symptomat
lung
transplant
patient
treat
iv
ribavirin
plu
corticosteroid
oral
ribavirin
plu
corticosteroid
oral
iv
ribavirin
inhal
ribavirin
plu
corticosteroid
ivig
palivizumab
highlight
lack
consensu
treatment
strategi
popul
recommend
hsct
patient
infecti
diseas
work
parti
german
societi
haematolog
medic
oncolog
recommend
ivig
gener
ribavirin
particular
rsv
patient
cancer
larg
base
data
hsct
recipi
guidelin
unit
kingdom
recommend
inhal
ribavirin
ivig
allogen
hsct
recipi
either
lrti
urti
risk
factor
progress
lrti
also
suggest
oral
ribavirin
inhal
form
avail
outsid
guidelin
recommend
sever
prospect
retrospect
studi
publish
treatment
rsv
hsct
patient
despit
avail
literatur
commonli
accept
approach
report
improv
outcom
treatment
rsv
hsct
patient
found
inhal
oral
iv
ribavirin
well
combin
ribavirin
ivig
palivizumab
andor
rsvspecif
ivig
support
treatment
urti
stage
progress
lrti
systemat
review
avail
retrospect
studi
report
form
ribavirin
alon
combin
immunomodulatori
agent
effect
prevent
progress
urti
lrti
trend
toward
better
outcom
inhal
ribavirin
plu
immunomodul
although
neg
studi
potenti
less
like
achiev
public
data
avail
suggest
adjunct
corticosteroid
use
palivizumab
alon
improv
outcom
complic
assess
rsv
treatment
sot
hsct
patient
recent
report
good
outcom
minim
intervent
immunocompromis
pediatr
patient
diagnos
symptomat
rsv
without
mortal
despit
receiv
direct
therapi
anoth
analysi
pediatr
hsct
recipi
rsv
report
attribut
mortal
ribavirin
therapi
patient
manag
either
support
care
alon
immunoglobulin
therapi
although
unclear
rsvspecif
treatment
effect
intervent
potenti
effect
investig
drug
develop
treatment
aerosol
alnylam
pharmaceut
cambridg
small
interf
rna
target
rsv
nucleocapsid
messeng
rna
shown
earli
promis
potenti
prevent
bo
lung
transplant
recipi
rsv
anoth
agent
adma
biolog
inc
ramsey
nj
contain
standard
level
hightit
antirsv
neutral
antibodi
report
compassion
use
patient
rsv
lrti
alreadi
receiv
treatment
ribavirin
well
toler
show
least
increas
geometr
mean
titer
rsv
antibodi
adma
biolog
inc
ramsey
nj
new
immunoglobulin
formul
develop
use
plasma
collect
individu
test
hightit
antirsv
antibodi
earli
trial
show
signific
increas
antirsv
neutral
antibodi
administ
primari
immunodefici
patient
addit
sever
small
molecul
therapi
variou
stage
develop
includ
earli
clinic
trial
one
molecul
oral
rsv
entri
inhibitor
report
significantli
lower
viral
load
total
mucu
weight
total
symptom
score
versu
placebo
healthi
adult
challeng
phase
trial
novel
small
molecul
lung
transplant
recipi
bone
marrow
transplant
bmt
patient
complet
enrol
result
pend
epidemiolog
risk
attribut
mortal
impact
influenza
infect
sot
patient
particularli
sever
especi
lung
transplant
recipi
rate
sever
influenza
lung
transplant
patient
report
infect
attribut
mortal
even
higher
mortal
caus
infect
lung
transplant
recipi
preexist
bo
grade
reprot
report
australian
lung
transplant
recipi
influenza
note
fev
declin
present
patient
prolong
allograft
dysfunct
report
sever
infect
larg
base
outcom
follow
pandem
howev
recent
retrospect
cohort
studi
brazilian
renal
transplant
recipi
influenza
report
incid
intens
care
unit
icu
admiss
mortal
higher
expect
similar
solid
organ
recipi
influenza
infect
hsct
patient
caus
signific
morbid
mortal
progress
urti
lrti
vari
wide
depend
report
found
adult
hsct
patient
patient
hematolog
malign
overal
mortal
risk
factor
either
present
lrti
progress
lrti
includ
alc
less
cellsml
lack
influenzadirect
therapi
increas
creatinin
level
delay
seek
care
signific
surviv
benefit
treat
influenzadirect
therapi
mortal
treat
patient
versu
mortal
untreat
patient
prevent
vaccin
remain
primari
focu
strongli
recommend
method
influenza
prevent
season
influenza
vaccin
cover
either
strain
influenza
base
antigen
character
previou
year
circul
strain
gener
quadrival
vaccin
cover
addit
influenza
b
strain
compar
trival
vaccin
without
interf
vaccin
respons
influenza
vaccin
avail
inactiv
intramuscular
intraderm
administr
live
attenu
intranas
formul
live
attenu
vaccin
recommend
immunocompromis
recipi
inactiv
vaccin
prefer
household
contact
overal
influenza
vaccin
respons
sot
hsct
patient
remain
variabl
base
popul
optim
time
vaccin
follow
sot
precis
determin
guidelin
american
societi
transplant
infecti
diseas
commun
practic
idsa
recommend
vaccin
month
transplant
report
immunogen
respons
influenza
vaccin
sot
show
wide
variat
depend
organ
transplant
year
assess
histor
rang
protect
seroprotect
respons
report
lung
transplant
recipi
adult
renal
transplant
recipi
greater
pediatr
liver
recipi
variou
adjuv
dose
strategi
evalu
effort
increas
immunogen
variabl
result
highdos
influenza
vaccin
contain
time
antigen
dose
standard
influenza
vaccin
earli
trial
report
increas
percentag
pediatr
sot
patient
achiev
increas
protect
titer
sever
like
explan
behind
report
variabl
respons
includ
organ
transplant
durat
time
transplant
degre
immunosuppress
impact
immunosuppress
immunogen
show
mycophenol
mofetil
consist
associ
decreas
respons
wherea
sirolimu
associ
increas
vaccin
respons
concern
potenti
develop
human
leukocyt
antigen
alloantibodi
follow
adjuv
pandem
influenza
vaccin
evalu
acut
reject
follow
influenza
immun
conduct
subsequ
postauthor
safeti
studi
follow
vaccin
found
increas
risk
acut
reject
associ
vaccin
season
influenza
immun
also
found
increas
risk
acut
reject
similar
sot
patient
influenza
immun
recommend
hsct
recipi
less
effect
compar
healthi
control
respons
rate
influenza
hsct
vari
base
time
transplant
influenza
seasonyear
studi
degre
immunosuppress
rate
seroconvers
typic
addit
encourag
report
increas
immunogen
highdos
inactiv
influenza
vaccin
compar
standard
dose
although
inactiv
influenza
vaccin
strongli
recommend
sot
hsct
recipi
approach
suggest
prevent
infect
addit
use
treatment
influenza
oseltamivir
zanamivir
also
approv
influenza
chemoprophylaxi
prospect
studi
predominantli
adult
sot
recipi
found
daili
oseltamivir
week
season
influenza
circul
significantli
reduc
incid
laboratoryconfirm
influenza
determin
revers
transcript
pcr
oseltamivir
given
day
also
report
effect
prevent
influenza
infect
hematologyhsct
inpati
unit
nosocomi
outbreak
treatment
earli
treatment
antivir
drug
shown
improv
outcom
reduc
hospit
admiss
mechan
ventil
use
mainstay
treatment
influenza
neuraminidas
inhibitor
nai
oseltamivir
peramivir
zanamivir
influenza
protein
inhibitor
amantadin
rimantadin
activ
influenza
longer
recommend
signific
resist
circul
influenza
strain
literatur
treatment
influenza
sot
hsct
reliabl
reproduc
maximum
benefit
seen
earlier
cours
virusspecif
therapi
initi
pandem
season
sot
recipi
treat
antivir
agent
within
hour
symptom
onset
significantli
less
like
vs
requir
icu
admiss
although
treatment
within
hour
optim
benefit
shown
even
delay
treatment
expert
therefor
endors
influenzaspecif
antivir
treatment
sot
hsct
patient
influenza
point
ill
oseltamivir
oral
nai
indic
treatment
influenza
b
adult
children
week
age
recommend
durat
treatment
day
immunocompet
children
adult
gener
treatment
recommend
practic
sot
patient
influenza
day
oseltamivir
well
although
day
oseltamivir
typic
treatment
durat
report
treatment
day
longer
patient
persist
symptom
clinic
trial
also
investig
conventionaldos
versu
doubledos
oseltamivir
day
immunocompromis
patient
result
yet
releas
clinicaltrialsgov
zanamivir
inhal
nai
approv
treatment
influenza
b
adult
children
year
age
older
zanamivir
use
less
frequent
oral
oseltamivir
like
deliveri
rout
rare
report
inhal
zanamivir
failur
peramivir
activ
influenza
b
current
iv
nai
approv
clinic
use
patient
age
year
older
iv
formul
zanamivir
oseltamivir
investig
clinic
trial
gener
less
experi
peramivir
compar
oral
oseltamivir
publish
report
clinic
effect
reduct
viral
load
encourag
peramivir
viabl
treatment
option
especi
patient
oral
inhal
antivir
optim
rout
pandem
influenza
strain
also
notabl
increas
frequenc
nai
resist
strain
howev
nai
resist
current
uncommon
overal
incid
isol
remain
area
grow
concern
frequent
neuraminidas
mutat
substitut
result
highlevel
oseltamivir
resist
reduc
peramivir
suscept
gener
preserv
zanamivir
activ
option
oseltamivirresist
influenza
limit
inhal
zanamivir
may
activ
mani
case
peramivir
report
effect
patient
oseltamivirresist
influenza
shown
encourag
result
prevent
lethal
mous
model
nairesist
influenza
model
ansun
biopharma
san
diego
ca
recombin
fusion
protein
remov
sialic
acid
receptor
influenza
bind
entri
cell
potenti
inhibit
influenza
parainfluenza
infect
shown
promis
vitro
result
activ
oseltamivirresist
influenza
strain
addit
test
versu
sever
nairesist
strain
ongo
asid
advanc
support
care
specif
adjunct
therapi
routin
recommend
corticosteroid
shown
decreas
need
mechan
ventil
progress
lrti
cost
prolong
viral
shed
therefor
although
corticosteroid
routin
recommend
corticosteroid
indic
anoth
reason
reject
gvhd
worsen
infect
influenza
clear
reason
withhold
steroid
epidemiolog
risk
attribut
mortal
adenoviru
doublestrand
dna
viru
made
immunolog
distinct
type
serotyp
commonli
associ
pneumonia
nonimmunocompromis
patient
adenoviru
typic
caus
selflimit
diseas
uri
conjunct
andor
gastroenter
adenoviru
infect
immunocompromis
patient
rang
asymptomat
viremia
signific
local
dissemin
diseas
contrast
mani
communityacquir
respiratori
virus
adenovir
infect
occur
primari
acquisit
reactiv
viru
studi
viral
reactiv
link
time
immun
reconstitut
tcell
count
depend
patient
factor
clinic
diseas
immunocompromis
patient
includ
pneumonia
hepat
coliti
hemorrhag
cystiti
enceph
retrospect
cohort
rvi
pediatr
sot
hsct
oncolog
patient
adenovir
infect
associ
greatest
length
stay
specif
viru
increas
risk
morbid
mortal
relat
rvi
odd
ratio
ci
p
adenovir
infect
report
renal
liver
small
bowel
lung
heart
transplant
recipi
although
asymptomat
associ
sever
diseas
although
adenovir
infect
hsct
like
caus
sever
diseas
sot
report
graft
infect
reject
adenoviru
essenti
sot
popul
infect
lung
recipi
common
seri
multipl
report
sever
infect
includ
graft
loss
progress
bo
death
infect
hsct
recipi
sever
associ
signific
mortal
adult
hsct
recipi
adenoviru
viremia
treat
antivir
almost
develop
invas
adenovir
diseas
die
infect
adenovir
lrti
dissemin
diseas
gener
carri
greatest
mortal
pediatr
hsct
patient
report
treatment
treatment
option
adenovir
infect
diseas
limit
current
approv
antivir
agent
treatment
report
recoveri
reduc
immun
suppress
alon
make
need
therapi
optim
time
intervent
uncertain
viral
infect
sot
hsct
patient
immunosuppress
reduct
recommend
possibl
cidofovir
approv
treatment
cmv
retin
patient
acquir
immunodefici
syndrom
common
antivir
use
treatment
cidofovir
nucleotid
analogu
inhibit
viral
dna
polymeras
broad
antivir
activ
dna
virus
herpesvirus
adenoviru
although
cidofovir
vitro
activ
adenoviru
gener
accept
standard
care
cidofovir
treatment
efficaci
controversi
dose
cidofovir
gener
mgkg
iv
everi
day
mgkg
iv
time
per
week
often
conjunct
probenecid
hydrat
cidofovir
nephrotox
dose
depend
common
reason
discontinu
therapi
altern
therapi
includ
ribavirin
combin
cidofovir
plu
ivig
report
limit
data
routin
recommend
use
investig
adenoviru
therapi
new
antivir
develop
altern
treatment
modal
may
addit
option
futur
brincidofovir
oral
bioavail
lipid
conjug
cidofovir
potent
vitro
activ
adenoviru
shown
promis
result
treatment
seriou
invas
adenoviru
infect
asymptomat
viremia
recogn
vital
role
tcell
immun
control
viral
infect
loss
immun
hsct
sot
use
adopt
tcell
immun
promis
well
adopt
tcell
immun
use
donor
virusspecif
tcell
treat
infect
report
safe
effect
perform
earli
cours
infect
adopt
tcell
transfer
gener
limit
center
predominantli
hsct
recipi
time
expertis
need
cell
prepar
recent
method
may
allow
shorter
gener
time
access
therapi
parainfluenza
epidemiolog
risk
factor
attribut
mortal
parainfluenza
viru
piv
singlestrand
envelop
rna
viru
distinct
serotyp
type
serotyp
vari
season
diseas
associ
pneumonia
bronchiol
yearround
activ
peak
spring
summer
common
caus
pediatr
laryngotracheobronch
croup
typic
peak
fall
winter
infect
rare
associ
diseas
retrospect
analysi
rvi
pediatr
immunocompromis
patient
report
rvi
sot
patient
caus
piv
parainfluenza
infect
present
commonli
urti
without
lrti
symptom
less
frequent
lrti
alon
although
previou
report
signific
mortal
sot
recipi
caus
piv
seri
recent
public
lung
organ
recipi
report
decreas
mortal
retrospect
report
place
incid
piv
infect
follow
hsct
greater
incid
children
adult
lrti
hsct
associ
high
morbid
mortal
risk
factor
lrti
caus
piv
lymphopenia
cellsmm
neutropenia
cellsml
apach
acut
physiolog
chronic
health
evalu
ii
score
greater
myeloabl
condit
highdos
corticosteroid
gvhd
coinfect
report
risk
factor
mortal
hsct
includ
lrti
earli
infect
mismatch
relat
donor
apach
ii
score
greater
new
oxygen
requir
diagnosi
low
monocyt
count
cellml
highdos
steroid
use
mgkgd
seri
hsct
patient
piv
lrti
mechan
ventil
necessari
attribut
mortal
recent
public
report
mortal
hsct
recipi
probabl
proven
parainfluenza
lrti
treatment
current
fdaapprov
antivir
treatment
parainfluenza
diseas
treatment
support
includ
reduct
immunosuppress
ribavirin
andor
ivig
use
label
parainfluenza
infect
variabl
result
definit
evid
efficaci
investig
parainfluenza
viru
therapi
discuss
previous
nairesist
influenza
potenti
inhibit
piv
bind
respiratori
epitheli
cell
inhal
treatment
typic
administ
via
dri
powder
inhal
day
use
compassion
use
clinic
trial
protocol
hsct
sot
recipi
includ
lung
transplant
patient
publish
report
shown
encourag
result
includ
reduct
piv
quantit
viral
load
overal
outcom
addit
intrigu
studi
examin
impact
cholesterol
reduc
agent
gemfibrozil
lovastatin
disrupt
viral
assembl
piv
rsv
influenza
report
parainfluenzaspecif
tcell
gener
healthi
donor
may
also
ultim
lead
effect
adopt
tcell
therapi
piv
epidemiolog
risk
factor
attribut
mortal
human
metapneumoviru
hmpv
rna
viru
identifi
paramyxoviru
famili
rsv
parainfluenza
typic
caus
selflimit
urti
immunocompet
person
hmpv
found
worldwid
occur
predominantli
late
winter
spring
month
often
follow
rsv
season
mani
communityacquir
rvi
sot
hsct
patient
progress
upper
respiratori
tract
lower
respiratori
tract
associ
increas
morbid
mortal
hmpv
welldocu
caus
symptomat
asymptomat
infect
lung
transplant
recipi
retrospect
popul
symptomat
adult
lung
transplant
recipi
hmpv
posit
via
nasopharyng
aspir
bal
rvi
asymptomat
wherea
other
develop
sever
pneumonia
acut
graft
dysfunct
rhinorrhea
cough
sputum
product
frequent
report
symptom
mortal
caus
acut
respiratori
distress
syndrom
graft
reject
also
report
identif
replic
hmpv
respiratori
sampl
seen
simultan
biopsyproven
graft
reject
suggest
potenti
associ
hmpv
acut
reject
infect
hsct
patient
variabl
well
recent
review
report
overal
incid
analysi
found
lrti
occur
hmpv
infect
hsct
recipi
mortal
greatest
lrti
mortal
caus
hmpv
infect
report
high
progress
urti
lrti
seen
hsct
recipi
associ
steroid
use
mgkg
low
lymphocyt
count
cellsmm
onset
infect
less
day
hsct
current
approv
antivir
prevent
treatment
hmpv
rsv
ribavirin
report
vitro
activ
hmpv
efficaci
ribavirin
hmpv
infect
reliabl
shown
report
lung
transplant
recipi
oral
ribavirin
result
quicker
return
baselin
decreas
incid
subsequ
bo
case
report
surviv
iv
inhal
ribavirin
howev
report
small
singlecent
studi
includ
control
popul
addit
studi
abl
identifi
similar
benefici
effect
ribavirin
hmpv
treatment
investig
human
metapneumoviru
therapi
adopt
tcell
transfer
yet
achiev
hmpvspecif
cell
gener
work
ongo
also
report
vitro
mous
model
human
monoclon
antibodi
prophylact
therapeut
hmpv
infect
cytomegaloviru
epidemiolog
risk
factor
attribut
mortal
cytomegaloviru
cmv
bherpesviru
well
recogn
signific
pathogen
immunocompromis
patient
cmv
report
affect
heart
lung
transplant
recipi
hsct
patient
although
cmv
caus
wide
array
infect
asymptomat
tissueinvas
diseas
cmv
pneumonitispneumonia
particular
concern
thorac
transplant
recipi
diagnosi
proven
cmv
pneumon
base
compat
clinic
sign
andor
symptom
document
cmv
lung
tissu
tradit
tissueinvas
cmv
base
histopatholog
immunohistochem
ihc
find
consist
tissu
invas
biopsi
cmv
cultur
quantit
nucleic
acid
amplif
test
tissu
sampl
difficult
interpret
posit
find
could
indic
tissueinvas
diseas
shed
set
activ
viremia
recent
updat
definit
cmv
pneumonia
includ
proven
probabl
possibl
cmv
pneumonia
proven
diseas
still
reli
identif
viral
antigen
inclus
bodi
via
immunohistochemistri
biopsi
materi
probabl
cmv
pneumonia
defin
compat
symptom
plu
cmv
detect
via
viral
isol
cultur
quantit
cmv
dna
bal
fluid
definit
cutoff
cmv
dna
load
set
cmv
pneumonia
howev
report
suggest
greater
iuml
possibl
cutoff
possibl
cmv
pneumonia
suggest
base
posit
quantit
pcr
perform
biopsi
tissu
risk
factor
cmv
diseas
report
advanc
age
reduceddos
valganciclovir
delayedonset
cmv
pneumon
day
posttranspl
donor
posit
cmv
serolog
asymptomat
cmv
infect
cmv
diseas
time
associ
increas
mortal
lung
transplant
recipi
cmv
hsct
patient
also
caus
wide
array
clinic
manifest
cmv
pneumonia
seriou
result
mortal
approxim
cmv
reactiv
alon
associ
lower
overal
mortal
follow
hsct
incid
cmv
pneumonia
unclear
larg
difficulti
definit
diagnosi
autopsi
studi
patient
cancer
hsct
report
incid
cmv
pneumonia
risk
factor
associ
cmvattribut
mortal
includ
femal
sex
lymphopenia
mechan
ventil
onset
diagnost
classif
cmv
pneumonia
pneumon
discuss
earlier
sot
iv
ganciclovir
gcv
oral
valganciclovir
without
cmv
immunoglobulin
cmvig
agent
recommend
prophylaxi
cmv
infect
sot
recipi
common
strategi
use
univers
prophylaxi
versu
preemptiv
therapi
consensu
recommend
favor
univers
prophylaxi
highrisk
heart
lung
recipi
risk
stratif
organ
transplant
recipi
reli
heavili
donor
recipi
cmv
serolog
result
transplant
donor
cmv
immunoglobulin
ig
g
posit
pair
recipi
igg
neg
consid
highest
risk
group
recipi
cmv
gener
consid
low
risk
although
communityacquir
infect
occur
posttranspl
patient
variabl
classifi
intermediaterisk
highrisk
often
center
depend
recommend
durat
prophylaxi
vari
base
organ
system
risk
stratif
heart
transplant
recipi
recommend
minimum
durat
cmv
prophylaxi
month
lung
transplant
recipi
minimum
recommend
durat
month
advoc
longer
even
indefinit
prophylaxi
center
use
indefinit
prophylaxi
lung
transplant
recipi
report
low
incid
cmv
infect
must
balanc
report
associ
gcvresist
cmv
prolong
cmv
prophylaxi
incid
gcvresist
infect
case
recipi
minimum
durat
lung
month
month
heart
recipi
popul
routin
use
cmv
prophylaxi
gener
recommend
sever
publish
report
potenti
benefit
addit
sole
use
cmvig
prophylaxi
limit
data
support
routin
use
addit
cmvig
routin
recommend
recent
consensu
guidelin
note
expert
add
cmvig
intermedi
higherrisk
recipi
random
studi
indic
cmvig
better
gcv
valganciclovir
alon
oppos
sot
recipi
hsct
patient
posit
cmv
serolog
transplant
higher
risk
reactiv
nonrelapserel
mortal
prevent
strategi
follow
hsct
similar
gener
consist
either
univers
prophylaxi
least
day
follow
hsct
preemptiv
approach
latter
commonli
report
practic
also
report
suggest
immunosuppress
choic
alter
cmv
infect
risk
lower
incid
cmv
infect
report
patient
treat
regimen
includ
mammalian
target
rapamycin
mtor
inhibitor
although
result
consist
reproduc
expert
recommend
consid
use
mtor
inhibitor
presenc
clinic
relev
recurr
gcvresist
cmv
infect
cmv
vaccin
evalu
sever
candid
vaccin
assess
clinic
trial
includ
live
attenu
recombin
glycoprotein
b
gb
dna
plasmid
viruslik
particl
system
investig
immunocompromis
patient
report
safeti
cmv
dna
vaccin
candid
chimer
peptid
vaccin
hsct
earli
evid
potenti
clinic
benefit
well
similarli
phase
trial
adjuv
gb
vaccin
versu
placebo
pretranspl
liver
kidney
patient
show
reduc
cmv
viremia
day
gcv
therapi
follow
transplant
greatest
effect
seen
cmv
seroneg
patient
therefor
although
current
cmv
vaccin
candid
yet
readi
clinic
use
avail
data
plu
number
clinic
trial
either
plan
ongo
immunocompromis
patient
encourag
iv
gcv
oral
valganciclovir
commonli
use
treatment
cmv
infect
diseas
foscarnet
cidofovir
activ
agent
well
gener
reserv
gcvresist
infect
hsct
recipi
concern
potenti
bone
marrow
suppress
caus
gcv
preengraft
period
cmvig
report
effect
sever
public
may
role
certain
set
cmvig
often
use
cmv
pneumonia
hsct
recipi
although
recent
analysi
fail
find
signific
improv
adjunct
ivig
cmvig
administr
popul
consensu
guidelin
cmv
treatment
sot
recipi
recommend
consider
adjunct
ivig
cmvig
recurr
cmv
diseas
thorac
organ
recipi
adjunct
therapi
case
hypogammaglobulinemia
investig
cytomegaloviru
therapi
investig
drug
therapi
cmv
prevent
treatment
current
develop
andor
test
clinic
trial
letermovir
interact
compon
viral
dna
cleavag
packag
report
effect
reduc
cmv
infect
hsct
recipi
reduc
viral
load
sot
patient
maribavir
competit
inhibitor
fail
show
noninferior
cmv
prevent
liver
transplant
patient
hsct
recipi
current
investig
use
cmv
infect
refractori
gcv
valganciclovir
foscarnet
cidofovir
clinicaltrialsgov
brincidofovir
referenc
earlier
adenoviru
shown
reduc
cmv
event
compar
placebo
hsct
recipi
addit
adopt
tcell
therapi
cmv
diseas
report
effect
lung
transplant
recipi
well
sever
hsct
recipi
herp
simplex
viru
varicella
zoster
viru
aherpesvirus
common
caus
infect
immunocompet
immunocompromis
person
immunocompromis
patient
hsv
caus
wide
varieti
clinic
infect
asymptomat
oropharyng
shed
mucocutan
dissemin
diseas
includ
pneumon
hsv
pneumon
uncommon
era
antivir
prophylaxi
thorac
transplant
hsct
recipi
reportedli
greatest
risk
similar
cmv
pneumon
recommend
diagnost
test
hsv
pneumon
tissu
histopatholog
ihc
hsv
posit
bal
pcr
test
hsv
may
repres
contamin
oropharyng
shed
iv
acyclovir
treatment
choic
sever
dissemin
hsv
includ
pneumon
recommend
continu
iv
acyclovir
resolut
day
time
oral
medic
may
given
vzv
anoth
herpesviru
also
caus
signific
diseas
sot
hsct
recipi
common
manifest
vzv
primari
varicella
chickenpox
suscept
seroneg
patient
herp
zoster
shingl
previou
vzv
infect
vaccin
viscer
dissemin
common
hsct
less
common
sot
dissemin
diseas
includ
infect
lung
tissu
result
vzv
pneumonia
signific
morbid
mortal
risk
dissemin
increas
acut
chronic
gvhd
well
increas
immunosuppres
iv
acyclovir
also
recommend
treatment
dissemin
invas
vzv
least
day
potenti
longer
patient
extens
involv
rvi
common
sot
hsct
recipi
caus
broad
array
infect
rang
asymptomat
signific
virusassoci
mortal
although
potenti
new
andor
novel
therapeut
option
evalu
current
treatment
option
remain
limit
immunocompromis
patient
gener
consist
support
care
reduct
immunosuppress
avail
antivir
medic
prevent
measur
infect
control
appropri
immun
remain
vital
